LPAR5 and ovarian serous cystadenocarcinoma: Subsequent survival analysis showed that in Brain Lower Grade Glioma (LGG) and ovarian serous cystadenocarcinoma (OV), high LPAR5 expression predicted a worse prognosis, whereas in Rectum Adenocarcinoma (READ), Skin Cutaneous Melanoma (SKCM) and Thyroid carcinoma (THCA), high LPAR5 expression predicted a better prognosis (Figure 13B).